IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2021i21p11172-d663720.html
   My bibliography  Save this article

Evaluation of Residual Infectivity after SARS-CoV-2 Aerosol Transmission in a Controlled Laboratory Setting

Author

Listed:
  • Luisa Zupin

    (Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria 65/1, 34137 Trieste, Italy)

  • Sabina Licen

    (Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy)

  • Margherita Milani

    (Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume 447, 34137 Trieste, Italy)

  • Libera Clemente

    (Ospedale San Polo, Azienda Sanitaria Universitaria Giuliano Isontina, Via Luigi Galvani 1, 34074 Monfalcone, Italy)

  • Lorenzo Martello

    (Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy)

  • Sabrina Semeraro

    (INSTM National Interuniversity Consortium of Materials Science and Technology, Via G. Giusti 9, 50121 Firenze, Italy)

  • Francesco Fontana

    (Ospedale San Polo, Azienda Sanitaria Universitaria Giuliano Isontina, Via Luigi Galvani 1, 34074 Monfalcone, Italy)

  • Maurizio Ruscio

    (Ospedale Maggiore, Azienda Sanitaria Universitaria Giuliano Isontina, Piazza dell’Ospitale 1, 34129 Trieste, Italy)

  • Alessandro Miani

    (Department of Environmental Science and Policy, University of Milan, Via Festa del Perdono 7, 20122 Milano, Italy)

  • Sergio Crovella

    (Department of Biological and Environmental Sciences, College of Arts and Sciences, University of Qatar, Doha 2713, Qatar
    These authors contributed equally.)

  • Pierluigi Barbieri

    (Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy
    INSTM National Interuniversity Consortium of Materials Science and Technology, Via G. Giusti 9, 50121 Firenze, Italy
    These authors contributed equally.)

Abstract

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is mainly transmitted through respiratory droplets, aerosols, or direct contact with fomites from an infected subject. It has been reported that SARS-CoV-2 is stable and viable in aerosol up to 16 h in controlled laboratory conditions. However, the aerosolization conditions varied a lot between the studies. In this work, an experimental laboratory model of SARS-CoV-2 aerosolization was established, employing an impinger nebulizer, a cylindrical chamber for aerosol travel, and a SKC biosampler for the collection of particles. The efficiency of the system was assessed based on the molecular determination of the viral load in the nebulizer after the aerosolization and in the aerosol collected at the end of the travel. Moreover, the residual infectivity was tested in vitro on the Vero E6 cell line, through the observation of the cytopathic effect (CPE), and the quantification of the viral load in the supernatants at 7 days post inoculation (dpi). A high RNA viral load was found in the SKC biosampler after aerosolization, indicating that it was possible to transport a high virus titer through the 30-cm chamber with all the dilutions (initial 10 5 , 10 4 , 10 3 plaque forming unit—PFU/mL). At the 7 dpi, an increment of the RNA viral load was determined for the dilutions 10 5 and 10 4 PFU/mL tested, while only the initial 10 5 PFU/mL resulted in visible CPE. Our findings allowed us to achieve the resilience of SARS-CoV-2 in aerosol form, at a concentration comparable to those reported for clinical samples. This mode of transmission should be considered for the mitigation and preventive measures to counteract SARS-CoV-2 spreading.

Suggested Citation

  • Luisa Zupin & Sabina Licen & Margherita Milani & Libera Clemente & Lorenzo Martello & Sabrina Semeraro & Francesco Fontana & Maurizio Ruscio & Alessandro Miani & Sergio Crovella & Pierluigi Barbieri, 2021. "Evaluation of Residual Infectivity after SARS-CoV-2 Aerosol Transmission in a Controlled Laboratory Setting," IJERPH, MDPI, vol. 18(21), pages 1-14, October.
  • Handle: RePEc:gam:jijerp:v:18:y:2021:i:21:p:11172-:d:663720
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/21/11172/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/18/21/11172/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Luisa Zupin & Francesco Fontana & Rossella Gratton & Margherita Milani & Libera Clemente & Lorella Pascolo & Maurizio Ruscio & Sergio Crovella, 2021. "SARS-CoV-2 Short-Time Infection Produces Relevant Cytopathic Effects in Vero E6 Cell Line," IJERPH, MDPI, vol. 18(17), pages 1-7, August.
    2. Soren Alexandersen & Anthony Chamings & Tarka Raj Bhatta, 2020. "SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication," Nature Communications, Nature, vol. 11(1), pages 1-13, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sabrina Semeraro & Anastasia Serena Gaetano & Luisa Zupin & Carlo Poloni & Elvio Merlach & Enrico Greco & Sabina Licen & Francesco Fontana & Silvana Leo & Alessandro Miani & Francesco Broccolo & Pierl, 2022. "Operative Protocol for Testing the Efficacy of Nasal Filters in Preventing Airborne Transmission of SARS-CoV-2," IJERPH, MDPI, vol. 19(21), pages 1-12, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Shiv Gandhi & Jonathan Klein & Alexander J. Robertson & Mario A. Peña-Hernández & Michelle J. Lin & Pavitra Roychoudhury & Peiwen Lu & John Fournier & David Ferguson & Shah A. K. Mohamed Bakhash & M. , 2022. "De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    2. Ella Borberg & Eran Granot & Fernando Patolsky, 2022. "Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    3. Sabrina Semeraro & Anastasia Serena Gaetano & Luisa Zupin & Carlo Poloni & Elvio Merlach & Enrico Greco & Sabina Licen & Francesco Fontana & Silvana Leo & Alessandro Miani & Francesco Broccolo & Pierl, 2022. "Operative Protocol for Testing the Efficacy of Nasal Filters in Preventing Airborne Transmission of SARS-CoV-2," IJERPH, MDPI, vol. 19(21), pages 1-12, October.
    4. Rúbens Prince dos Santos Alves & Julia Timis & Robyn Miller & Kristen Valentine & Paolla Beatriz Almeida Pinto & Andrew Gonzalez & Jose Angel Regla-Nava & Erin Maule & Michael N. Nguyen & Norazizah Sh, 2024. "Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    5. Orsolya Anna Pipek & Anna Medgyes-Horváth & József Stéger & Krisztián Papp & Dávid Visontai & Marion Koopmans & David Nieuwenhuijse & Bas B. Oude Munnink & István Csabai, 2024. "Systematic detection of co-infection and intra-host recombination in more than 2 million global SARS-CoV-2 samples," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    6. Yunxi Liu & Nicolae Sapoval & Pilar Gallego-García & Laura Tomás & David Posada & Todd J. Treangen & Lauren B. Stadler, 2024. "Crykey: Rapid identification of SARS-CoV-2 cryptic mutations in wastewater," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    7. Uddhav Timilsina & Supawadee Umthong & Emily B. Ivey & Brandon Waxman & Spyridon Stavrou, 2022. "SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5," Nature Communications, Nature, vol. 13(1), pages 1-15, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:21:p:11172-:d:663720. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.